CHRNB2 Gene Epilepsy, nocturnal frontal lobe type 3 NGS Genetic Test
Short Name: CHRNB2 NFLE Type 3 NGS
Also known as: CHRNB2 Epilepsy, Nocturnal Frontal Lobe Epilepsy Type 3, NFLE3
CHRNB2 Gene Epilepsy, nocturnal frontal lobe type 3 NGS Genetic Test test available at DNA Labs India for ₹20,000. Uses Next Generation Sequencing (NGS) on Blood or Extracted DNA or One drop Blood on FTA Card samples. Results in Reports are usually delivered within 3 to 4 weeks from sample receipt.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr SULOCHANA HEMCHANDRA HOLLA
Consultant Medical Geneticist · Reg: 8532
Last reviewed: September 7, 2026
Overview
To identify pathogenic variants in the CHRNB2 gene in individuals with clinical features suggestive of nocturnal frontal lobe epilepsy, confirm the genetic diagnosis of NFLE Type 3, guide treatment decisions, and offer reproductive and recurrence risk counselling to families.
- Test Code
- 4084
- Price
- ₹20,000
- Sample Type
- Blood or Extracted DNA or One drop Blood on FTA Card
- Result Time
- Reports are usually delivered within 3 to 4 weeks from sample receipt.
- Fasting Required
- No
- Method
- Next Generation Sequencing (NGS)
Sample Collection
A genetic counselling session is recommended prior to testing to discuss the benefits and limitations of the genetic test and to draw a three-generation pedigree. No fasting is required. Please carry previous medical records and imaging reports if available.
Method: Peripheral blood or FTA card spot
Laboratory Analysis
A small amount of blood is drawn from a vein in the arm, or a few drops are placed on an FTA card. The procedure is quick and routine.
Report Delivery
The sample is sent to the DNA Labs India laboratory. The patient may resume normal diet and activities immediately.
Timeline: Reports are usually delivered within 3 to 4 weeks from sample receipt.
Patient Instructions
About This Test
Who Should Get This Test
To identify pathogenic variants in the CHRNB2 gene in individuals with clinical features suggestive of nocturnal frontal lobe epilepsy, confirm the genetic diagnosis of NFLE Type 3, guide treatment decisions, and offer reproductive and recurrence risk counselling to families.
How to Prepare
- Ensure blood is collected in the provided EDTA tube and mixed gently.
- For FTA card, apply the labelled blood spots onto the card and dry completely.
- Transport samples at ambient temperature, avoiding direct sunlight and extreme heat.
- Clearly label the sample with the patient's name and unique ID.
Doctor's Notes
Reviewed by Dr SULOCHANA HEMCHANDRA HOLLA — MBBS, MD (Medical Genetics) · Reg. No. 8532
"In families with suspected inherited epilepsy syndromes, genetic testing of the CHRNB2 gene provides critical information for recurrence risk assessment and informed reproductive planning."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Hemolysed or clotted blood sample
- Insufficient sample quantity
- Mislabelled or unlabelled sample
- Sample in a container without anticoagulant
Understanding Your Results
Pathogenic
Confirms diagnosis of CHRNB2-related nocturnal frontal lobe epilepsy. Predictive testing of at-risk family members can be considered.
Likely Pathogenic
High likelihood of disease association. Additional evidence may be needed to confirm clinical diagnosis.
Variant of Uncertain Significance (VUS)
Insufficient evidence to determine disease causality. Family segregation analysis may be helpful.
Benign
No disease association. Does not explain patient's phenotype.
If you or a family member experience seizures while sleeping, consult a neurologist for a detailed evaluation and to determine if genetic testing is appropriate.
Limitations
- ⚠This test only analyses the CHRNB2 gene and does not rule out variants in other epilepsy-related genes.
- ⚠Large deletions/duplications may not be detected by standard NGS unless copy-number variant analysis is specifically performed.
- ⚠A negative result does not exclude a non-genetic cause of seizures.
- ⚠Variant of uncertain significance may require additional family studies.
Risks & Considerations
- ●Minimal risk of bruising, bleeding, or infection at the venipuncture site.
- ●No significant medical risks associated with genetic testing itself.
Interfering Factors
- ●Poor DNA quality
- ●Maternal cell contamination
- ●Sample mix-up
- ●Variants in non-coding regulatory regions not covered by NGS
Frequently Asked Questions
What is CHRNB2 gene epilepsy, nocturnal frontal lobe type 3?
How is CHRNB2-related epilepsy inherited?
What is the cost of the CHRNB2 gene NGS test?
What samples are accepted for this test?
How long will it take to get the test report?
Is genetic counselling necessary before the test?
What does a positive test result mean?
Can this test detect all types of epilepsy?
Is fasting required before blood collection?
Is the CHRNB2 NGS test available across India?
How is the CHRNB2 gene related to seizures?
Are there any risks in taking this genetic test?
Related Tests
Angelman Syndrome Test
₹10,000Duchenne / Becker Muscular Dystrophy (DMD / BMD) Gene Mutation Test
₹14,000Episodic Ataxia Type 1 Hotspot Test
₹11,500Episodic Ataxia Comprehensive Profile Hotspot Test
₹16,000Megalencephalic Leukoencephalopathy with Subcortical Cysts Van Der Knaap and Nalband MLC Gene Hotspot Mutation Test
₹7,500Analyzer 18 SMA 18 Test Panel
₹1,755Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.